Stock Movers Sanofi Falls, M&G Rises, Gap Down
May 30, 2025
Sanofi's shares took a hit after mixed results from a critical drug trial for a lung condition. Meanwhile, M&G saw a rise of up to 8.6% thanks to Dai-ichi Life acquiring a significant stake. On the other hand, Gap's stocks fell dramatically, facing a tariff impact of $300 million amid poor sales performance, which also affected Asian clothing brands. The market reacts strongly to these developments, revealing the interconnected nature of stock movements in the retail and pharmaceutical sectors.
AI Snips
Chapters
Transcript
Episode notes
Sanofi Trial Disappointment Impact
- Sanofi shares dropped around 7% after disappointing trial data for a lung condition drug.
- The drug was initially valued for its potential $5 billion peak sales but failed to meet expectations.
M&G Gains From Stake Acquisition
- M&G shares rose about 9% after Dai-ichi Life acquired a 15% stake in the UK insurer.
- This deal boosts cooperation and adds $6 billion in new asset management flows.
Gap's Sales and Store Closure Effects
- Gap's sales underperformed expectations, especially its Banana Republic brand, causing shares to fall 15% post-market.
- Gap stores closed in the UK, shifting sales to online, affecting local shopping experiences.